Drug Trial Radar · NCT04893486
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
May 6, 2021
Primary completion
Mar 13, 2023
Study completion Mar 13, 2023
Sponsor
- Lead sponsor
- Palvella Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be conducted at multiple centers in the United States where participants with Gorlin Syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. Participants will apply this topical product to their face once a day for 6 months. The study will be looking at the number of new BCCs that develop on the faces of all the participants during this time.
Conditions
- BCCs in Gorlin Syndrome Patients
Interventions
PTX-022Drug
QTORIN 3.9 % Sirolimus Topical Gel
Vehicle comparatorDrug
Vehicle comparator topical gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of new biopsy confirmed BCCs that develop on the face compared between the active and vehicle treatment armsTime frame: Month 6
- Incidence of dermatological, treatment emergent adverse events after treatment with activeTime frame: Month 6
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
Burke Pharmaceuticals Research
Hot Springs, Arkansas
Stanford Univeristy
Palo Alto, California
Park Avenue Dermatology
Orange Park, Florida
Ameriderm Research
Ormond Beach, Florida
Gwinett Clinical Research Center
Snellville, Georgia
Clinical Coordinating Center (Minnesota)
New Brighton, Minnesota
Mayo Clinic - Minnesota
Rochester, Minnesota
St. Louis University
St Louis, Missouri
Duke University
Durham, North Carolina
Penn State Hershey Medical Center
Hershey, Pennsylvania
DermResearch Inc
Austin, Texas
University of Utah
Murray, Utah
Virginia Clinical Research, Inc.
Norfolk, Virginia
St. Pancras Clinical Research
London, United Kingdom
Salford Foundation Trust
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.